Today we have an update on our previous blog highlighting Gilead’s Remdesivir.
The company has announced that in a US government run study, the experimental drug has yielded positive results. According to the study, Remdesivir has helped patients recover more quickly than standard care. As we mentioned in the previous blog, this experimental drug was originally developed to treat other viruses, and has not been approved for anywhere else in the world.
In another study released by Gilead, they say their experimental drug appears to be effective when given to patients over a five-day period as opposed to a 10-day period. The issue with these studies is that they do not have comparison groups, this is something we highlighted in our previous post in order to temper our expectations.
Nevertheless, these results mean more testing is on the way. Gilead believes more people can be treated with their drug and remain confident that it will continue to be effective.
A new trial un by the National Institute of Health is expected to sign up about 800 patients in hopes to get a definitive answer as to whether or not the drug is effective at treating Covid-19.
Remember to check back regularly at the ABN blog for more news about experimental drug trials related to Covid-19.